logo
episode-header-image
Aug 2019
7m 36s

Nephroprotektion durch SGLT-2-Inhibitore...

AMBOSS-Redaktion
About this episode
Revolution zur Behandlung chronischer Nierenerkrankungen?

Studientelegramm 73-2019-3/3

Titel der Studie: Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy

Autoren: Perkovic et al.

Journal: New England Journal of Medicine (NEJM)

AMBOSS-Inhalte: Therapie der chronischen Niereninsuffizienz, SGLT2-Inhibitoren, Studientelegramme zu SGLT-2-Inhibitoren

Up next
Jun 28
Diuretika: Worauf es therapeutisch ankommt
Sicher dosieren, gezielt therapieren: Tipps zur Diuretika-Anwendung 
58m 7s
Jun 14
Deprescribing: Medikamente richtig reduzieren und absetzen
Polymedikation im Blick: Sicher absetzen mit System 
54m 35s
May 31
Frauen und Alkohol: Neue Konsummuster
Weiblicher Alkoholkonsum: Risiken, aktuelle Entwicklungen, Handlungsempfehlungen 
39m 9s
Recommended Episodes
Sep 2021
Diabetes Core Update SGLT2s and Diabetic Kidney Disease
In this special episode on SGLT-2 inhibitors and CKD Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in decreasing progression of chronic kidney disease. This special episide is supported by independent educational grant from AstraZeneca. For more ... Show More
36m 4s
Aug 2022
S1 Episode 1: Chronic Kidney Disease and SGLT2 Inhibitors: Usage, Monitoring, and Possible Side Effects
Drs Sparks and Neuen discuss the proper use of SGLT2 inhibitors to prevent chronic kidney disease, including how to start them and monitor them and their possible side effects. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/vie ... Show More
24m 28s
Mar 2021
Diabetes Core Update Special Edition - SGLT2 Inhibitors Part 3: Beneficial Effects on Heart Failure Endpoints– March 2021
In this third episode of a three-part series on SGLT-2 inhibitors Drs. John Russell and Neil Skolnik discuss the effects of the SGLT-2 inhibitors in heart failure in persons with and without diabetes. In episode 1, Drs. Russell and Skolnik discussed an overview of the CVOTs for t ... Show More
17m 46s
Nov 2023
Freely Filtered 064: Freely Filtered with The Curbsiders Live at Kidney Week!
The Filtrate:Joel TopfSwapnil HiremathSophia AmbrusoAC GomezJosh WaitzmanJennie LinNayan AroraThe CurbsidersMatt F. Watto (@DoctorWatto)Paul Nelson Williams, America’s primary care physician (@PaulNWilliamz)With Special Guest:JD Foster (@KidneyVet)Sayed Tabatabai (@TheRealDoctorT ... Show More
1h 32m
Sep 2023
S2 Episode 4: Chronic Kidney Disease: FSGS, Genetic Testing, and APOL1
Join Drs Matthew Sparks and Kirk Campbell as they dive into the murky waters of focal segmental glomerular sclerosis. How do you diagnose? How do you treat? Tune in to find out. Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/vi ... Show More
27m 55s
Nov 2023
#279 - AMA #53: Metabolic health & pharmacologic interventions: SGLT-2 inhibitors, metformin, GLP-1 agonists, and the impact of statins
View the Show Notes Page for This Episode Become a Member to Receive Exclusive Content Sign Up to Receive Peter’s Weekly Newsletter In this “Ask Me Anything” (AMA) episode, Peter explores various pharmacologic tools commonly utilized to improve metabolic health and treat diabetes ... Show More
27m 10s
Aug 2020
Chapter 15: Nephrology (Part 3)
This episode is the last from the Nephrology chapter of Crush Step 1. Topics discussed include: - Pathology (Cont.) Tubular and Interstitial Disorders Azotemia and Renal Failure Urinary Tract Infections Malignancies and Benign Tumors of the Urinary Tract Congenital and Inherited ... Show More
42m 40s
Jun 2024
Episode 72: Nefecon for IgAN, The NefIgArd part B trial
The Filtrate:Joel TopfJosh WaitzmanWith Special Guest:Brad Rovin (@BradRovin) Chief of nephrology at The Ohio State University Wexner Medical Center, one of the authors of the Nefigard trial. Koyal Jain (@koyaljainMD) Program director of the GN Fellowship at University of North C ... Show More
1h 32m